Mehralizadeh H, et al. Cytokine sustained delivery for cancer therapy; special focus on stem cell-and biomaterial-based delivery methods. Pathol-Res Pract. 2023;247:154528.

Shabani S, Moghadam MF, Gargari SL. Isolation and characterization of a novel GRP78-specific single-chain variable fragment (scFv) using ribosome display method. Med Oncol. 2021;38(9):115.

Article  CAS  PubMed  Google Scholar 

Liu J, et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28.

Article  PubMed  PubMed Central  Google Scholar 

Kaboli PJ, et al. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Am J Cancer Res. 2022;12(4):1671.

Carlson RD, Flickinger JC Jr, Snook AE. Talkin’toxins: from Coley’s to modern cancerimmunotherapy. Toxins. 2020;12(4):241.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27(1):74–95. This review discussed how current approaches apply DC vaccines to improve anti-tumor immunity in clinic.

Article  CAS  PubMed  Google Scholar 

Okamoto M, et al. Dendritic cell-based vaccine for pancreatic cancer in Japan. World J Gastrointest Pharmacol Ther. 2016;7(1):133.

Article  PubMed  PubMed Central  Google Scholar 

Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449(7161):419–26.

Article  CAS  PubMed  Google Scholar 

Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1–22.

Article  CAS  PubMed  Google Scholar 

• Plumas J. Harnessing dendritic cells for innovative therapeutic cancer vaccines. Curr Opin Oncol. 2022;34(2):161–8. This article reviewed recent research using allogeneic DCs as alternatives to autologous DCs to develop innovative therapeutic cancer vaccines.

Article  CAS  PubMed  Google Scholar 

Abbasi S, et al. Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies. Cancer Med. 2023;12(7):7844–58.

Article  CAS  PubMed  Google Scholar 

Kozani PS, Shabani S. Adverse events and side effects of chimeric antigen receptor (CAR) t cell therapy in patients with hematologic malignancies. Trends Med Sci. 2021;1(1):620374.

Saxena M, et al. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360–78.

Article  CAS  PubMed  Google Scholar 

Andtbacka RH, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.

Article  CAS  PubMed  Google Scholar 

Ribas A, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2018;174(4):1031–2.

Article  CAS  PubMed  Google Scholar 

Harari A, et al. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat Rev Drug Discov. 2020;19(9):635–52.

Article  CAS  PubMed  Google Scholar 

Tolouei AE, et al. Gingival mesenchymal stem cell therapy, immune cells, and immunoinflammatory application. Mol Biol Rep. 2023:1–9.

Fu C, et al. DC-based vaccines for cancer immunotherapy Vaccines. 2020;8(4):706.

CAS  PubMed  Google Scholar 

Eisenbarth SC. Dendritic cell subsets in T cell programming: location dictates function. Nat Rev Immunol. 2019;19(2):89–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guermonprez P, et al. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20(1):621–67.

Article  CAS  PubMed  Google Scholar 

Patente TA, et al. Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy. Front Immunol. 2019;9:3176.

Article  PubMed  PubMed Central  Google Scholar 

Hilligan KL, Ronchese F. Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses. Cell Mol Immunol. 2020;17(6):587–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wculek SK, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24. This article reviewed different DC subsets immunity and tolerance in cancer settings and immunotherapy strategies.

Article  CAS  PubMed  Google Scholar 

Anderson DA III, et al. Genetic models of human and mouse dendritic cell development and function. Nat Rev Immunol. 2021;21(2):101–15.

Article  CAS  PubMed  Google Scholar 

Villani AC, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356(6335):eaah4573.

Article  PubMed  PubMed Central  Google Scholar 

Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 2018;154(1):3–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haniffa M, Collin M, Ginhoux F. Ontogeny and functional specialization of dendritic cells in human and mouse. Adv Immunol. 2013;120:1–49.

Article  CAS  PubMed  Google Scholar 

Haniffa M, Collin M, Ginhoux F. Identification of human tissue cross-presenting dendritic cells: a new target for cancer vaccines. Oncoimmunol. 2013;2(3): e23140.

Article  Google Scholar 

Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141+ (BDCA-3)+ DCs represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207(6):1247–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown CC, et al. Transcriptional basis of mouse and human dendritic cell heterogeneity. Cell. 2019;179(4):846–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamazaki C, et al. Critical roles of a dendritic cell subset expressing a chemokine receptor, XCR1. J Immunol. 2013;190(12):6071–82.

Article  CAS  PubMed  Google Scholar 

Dhodapkar MV, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193(2):233–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonaccorsi I, et al. Novel perspectives on dendritic cell-based immunotherapy of cancer. Immunol Lett. 2013;155(1–2):6–10.

Article  CAS  PubMed  Google Scholar 

Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010;33(4):464–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banchereau J, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61(17):6451–8.

CAS  PubMed  Google Scholar 

Mody N, et al. Dendritic cell-based vaccine research against cancer. Expert Rev Clin Immunol. 2015;11(2):213–32.

Article  CAS  PubMed  Google Scholar 

Trefzer U, et al. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer. 2000;85(5):618–26.

Article  CAS  PubMed  Google Scholar 

Trefzer U, et al. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine. 2005;23(17–18):2367–73.

Article  CAS  PubMed  Google Scholar 

Krause SW, et al. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother. 2002;25(5):421–8.

Article  CAS  PubMed  Google Scholar 

Maeng HM, et al. Phase I clinical trial of an autologous dendritic cell vaccine against HER2 shows safety and preliminary clinical efficacy. Front Oncol. 2021;11: 789078.

Article  CAS  PubMed  PubMed Central